These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 20686817)

  • 1. Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies.
    Schneider BJ; Kalemkerian GP; Bradley D; Smith DC; Egorin MJ; Daignault S; Dunn R; Hussain M
    Invest New Drugs; 2012 Feb; 30(1):249-57. PubMed ID: 20686817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer.
    Rathkopf D; Wong BY; Ross RW; Anand A; Tanaka E; Woo MM; Hu J; Dzik-Jurasz A; Yang W; Scher HI
    Cancer Chemother Pharmacol; 2010 May; 66(1):181-9. PubMed ID: 20217089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression.
    Reguart N; Rosell R; Cardenal F; Cardona AF; Isla D; Palmero R; Moran T; Rolfo C; Pallarès MC; Insa A; Carcereny E; Majem M; De Castro J; Queralt C; Molina MA; Taron M
    Lung Cancer; 2014 May; 84(2):161-7. PubMed ID: 24636848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I and pharmacokinetic study of docetaxel, irinotecan, and celecoxib in patients with advanced non-small cell lung cancer.
    Argiris A; Kut V; Luong L; Avram MJ
    Invest New Drugs; 2006 May; 24(3):203-12. PubMed ID: 16096702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I Study of Docetaxel and Temsirolimus in Refractory Solid Tumors.
    Amin M; Gao F; Terrero G; Picus J; Wang-Gillam A; Suresh R; Ma C; Tan B; Baggstrom M; Naughton MJ; Trull L; Belanger S; Fracasso PM; Lockhart AC
    Am J Clin Oncol; 2021 Sep; 44(9):443-448. PubMed ID: 34310349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer.
    Kotsakis A; Agelaki S; Vardakis N; Stathopoulos G; Vamvakas L; Kalykaki A; Kentepozidis N; Kontopodis E; Sfakiotaki G; Mavroudis D; Georgoulias V
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):415-22. PubMed ID: 21069335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer.
    Millward MJ; Zalcberg J; Bishop JF; Webster LK; Zimet A; Rischin D; Toner GC; Laird J; Cosolo W; Urch M; Bruno R; Loret C; James R; Blanc C
    J Clin Oncol; 1997 Feb; 15(2):750-8. PubMed ID: 9053501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium - an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879.
    Quinn DI; Tsao-Wei DD; Twardowski P; Aparicio AM; Frankel P; Chatta G; Wright JJ; Groshen SG; Khoo S; Lenz HJ; Lara PN; Gandara DR; Newman E
    Invest New Drugs; 2021 Jun; 39(3):812-820. PubMed ID: 33409898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapy.
    Tambo Y; Hosomi Y; Sakai H; Nogami N; Atagi S; Sasaki Y; Kato T; Takahashi T; Seto T; Maemondo M; Nokihara H; Koyama R; Nakagawa K; Kawaguchi T; Okamura Y; Nakamura O; Nishio M; Tamura T
    Invest New Drugs; 2017 Apr; 35(2):217-226. PubMed ID: 28138828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer.
    Dasari A; Gore L; Messersmith WA; Diab S; Jimeno A; Weekes CD; Lewis KD; Drabkin HA; Flaig TW; Camidge DR
    Invest New Drugs; 2013 Feb; 31(1):115-25. PubMed ID: 22415798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer].
    Li JL; Zhang XR; Liu JW; Chen ZY; Lin YC; Wang YD; Chen Q; Nan KJ; Song SP; Han FC; Zhu YZ; Li LY; Zheng YH; Chu DT
    Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):309-12. PubMed ID: 16875636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study.
    Hummel TR; Wagner L; Ahern C; Fouladi M; Reid JM; McGovern RM; Ames MM; Gilbertson RJ; Horton T; Ingle AM; Weigel B; Blaney SM
    Pediatr Blood Cancer; 2013 Sep; 60(9):1452-7. PubMed ID: 23554030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I dose escalation study of weekly docetaxel and carboplatin in elderly patients with nonsmall cell lung cancer.
    Kaira K; Tsuchiya S; Sunaga N; Yanagitani N; Watanabe S; Imai H; Hisada T; Ishizuka T; Saito R; Mori M
    Am J Clin Oncol; 2007 Feb; 30(1):51-6. PubMed ID: 17278895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Docetaxel in combination with carboplatin for the treatment of advanced non-small cell lung carcinoma: a multicentre phase I study.
    Giannakakis T; Ziras N; Kakolyris S; Mavroudis D; Androulakis N; Agelaki S; Parashos M; Sarra E; Dimou T; Hatzidaki D; Vlachonikolis J; Georgoulias V
    Eur J Cancer; 2000 Apr; 36(6):742-7. PubMed ID: 10762746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer.
    Moulder S; Dhillon N; Ng C; Hong D; Wheler J; Naing A; Tse S; La Paglia A; Dorr R; Hersh E; Boytim M; Kurzrock R
    Invest New Drugs; 2010 Oct; 28(5):634-40. PubMed ID: 19499186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of celecoxib and docetaxel in non-small cell lung cancer (NSCLC) patients with progression after platinum-based therapy.
    Schneider BJ; Kalemkerian GP; Kraut MJ; Wozniak AJ; Worden FP; Smith DW; Chen W; Gadgeel SM
    J Thorac Oncol; 2008 Dec; 3(12):1454-9. PubMed ID: 19057272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose Escalation Trial.
    Choi CYH; Wakelee HA; Neal JW; Pinder-Schenck MC; Yu HM; Chang SD; Adler JR; Modlin LA; Harsh GR; Soltys SG
    Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):16-21. PubMed ID: 28816142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination.
    Millward M; Price T; Townsend A; Sweeney C; Spencer A; Sukumaran S; Longenecker A; Lee L; Lay A; Sharma G; Gemmill RM; Drabkin HA; Lloyd GK; Neuteboom ST; McConkey DJ; Palladino MA; Spear MA
    Invest New Drugs; 2012 Dec; 30(6):2303-17. PubMed ID: 22080430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer.
    Ramalingam SS; Harvey RD; Saba N; Owonikoko TK; Kauh J; Shin DM; Sun SY; Strychor S; Tighiouart M; Egorin MJ; Fu H; Khuri FR
    Cancer; 2010 Aug; 116(16):3903-9. PubMed ID: 20564143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies.
    Schelman WR; Traynor AM; Holen KD; Kolesar JM; Attia S; Hoang T; Eickhoff J; Jiang Z; Alberti D; Marnocha R; Reid JM; Ames MM; McGovern RM; Espinoza-Delgado I; Wright JJ; Wilding G; Bailey HH
    Invest New Drugs; 2013 Dec; 31(6):1539-46. PubMed ID: 24114121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.